| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 04/06/2005 | CN1602917A 'Shengmai' formulation and its preparation process |
| 04/06/2005 | CN1602910A Manufacturing technique of anore treating Chinese traditional medicine |
| 04/06/2005 | CN1602907A Medicine for treating chronic bronchitis and asthma |
| 04/06/2005 | CN1602906A Medicine for treating rhinitis and its preparing process |
| 04/06/2005 | CN1602899A Chinese prepared drug formulation for stopping cough and eliminating sputum and its preparation process |
| 04/06/2005 | CN1602876A Dimethoxanate hydrochloride dripping pills and its preparation method |
| 04/06/2005 | CN1602869A Dripping pills of eprazinone hydrochloride and its preparation |
| 04/06/2005 | CN1602866A Dripping pills of tripelennamine hydrochloride and its preparation method |
| 04/06/2005 | CN1602862A Application of leflunomide in the preparation process of anti SARS virus medicine |
| 04/06/2005 | CN1602860A Dripping pills of clemastine fumarate and its preparation method |
| 04/06/2005 | CN1602853A Active constituent of traditional Chinese medicine capable of inhibiting SARS coronavirus infection and its bioactivity measuring method |
| 04/06/2005 | CN1602852A Sodium houttuyfonate injection and its preparation method |
| 04/06/2005 | CN1602848A Ambroxol hydrochloride drop pills and its preparation method |
| 04/06/2005 | CN1195778C Cell adhension inhibitors |
| 04/06/2005 | CN1195773C Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/06/2005 | CN1195755C Pyrrolo [2, 3-d] pyrimidine compounds |
| 04/06/2005 | CN1195539C Medicine for treating cough |
| 04/06/2005 | CN1195507C New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 G/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof |
| 04/06/2005 | CN1195494C Oral liquid mucoadhesive compositions |
| 04/05/2005 | US6875883 Forming a phenyl-thiazoles chemical intermediates for making antioxidants, ferrielectric liquid crystal dopant, picornaviral viricides, antiinflammatory agents, anti-asthma agents, and fibringoen antagonists |
| 04/05/2005 | US6875882 Ferroelectric liquid crystals, antihistamines, antiinflammatory agents, viricides |
| 04/05/2005 | US6875868 Pteridine compounds for the treatment of psoriasis |
| 04/05/2005 | US6875846 Heterologous polypeptide of the TNF family |
| 04/05/2005 | US6875779 Cyclooxygenase inhibitor |
| 04/05/2005 | US6875777 Compounds |
| 04/05/2005 | US6875767 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors |
| 04/05/2005 | US6875749 Methods of facilitating vascular growth |
| 04/05/2005 | US6875736 Methods for identifying RNA binding compounds |
| 04/05/2005 | US6875597 Comprises nucleotide sequences coding sulfotransferase for identifying modulators and designing drug delivery systems |
| 04/05/2005 | US6875570 Proteins and nucleic acids encoding same |
| 03/31/2005 | WO2005028482A1 Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases |
| 03/31/2005 | WO2005028463A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 03/31/2005 | WO2005028441A1 Cinnamoyl derivatives and use thereof |
| 03/31/2005 | WO2005028439A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 03/31/2005 | WO2005027956A1 Method of treating allergy and/or airway disease |
| 03/31/2005 | WO2005027935A1 Carbohydrate composition and its use for the preparation of a medicament for treating or preventing pulmonary inflammation or acute respiration distress syndrome |
| 03/31/2005 | WO2005027896A1 Concurrent drugs |
| 03/31/2005 | WO2005027893A1 HUMAN β-DEFENSIN SECRETION PROMOTER |
| 03/31/2005 | WO2004108133A3 Modulators of vr1 receptor |
| 03/31/2005 | WO2004064742A3 Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms |
| 03/31/2005 | WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 03/31/2005 | WO2003018756A3 Methods for preparing purified prostaglandin e synthase |
| 03/31/2005 | US20050070694 Antagonistic anti-htnfsf13b human antibodies |
| 03/31/2005 | US20050070691 Polypeptides of moraxella (branhamella) catarrhalis |
| 03/31/2005 | US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders |
| 03/31/2005 | US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity |
| 03/31/2005 | US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders |
| 03/31/2005 | US20050070581 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease |
| 03/31/2005 | US20050070574 Novel compounds |
| 03/31/2005 | US20050070572 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies |
| 03/31/2005 | US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors |
| 03/31/2005 | US20050070566 Imidazoquinoline derivatives |
| 03/31/2005 | US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions |
| 03/31/2005 | US20050070555 Aroyl pyridinones |
| 03/31/2005 | US20050070541 Enzyme inhibitors of cGMP-metabolizing phosphodiesterases, for TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION; chemical synthesis |
| 03/31/2005 | US20050070514 Administering phosphodiesterase 4 inhibitor in combination with beta agonist and an anti-inflammatory steroid |
| 03/31/2005 | US20050070491 Immunostimulatory nucleic acid molecules |
| 03/31/2005 | US20050070487 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
| 03/31/2005 | US20050070485 Phenylalanine derivatives |
| 03/31/2005 | US20050070477 Lung surfactant polypeptide, and at least one inhibitor of a mediator of tissue destruction; for example protease inhibitors; treating inflammatory lung conditions such as asthma, chronic obstructive pulmonary disease |
| 03/31/2005 | US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 03/31/2005 | US20050070468 Use of fk506 and analogues for treating allergic diseases |
| 03/31/2005 | US20050070005 High throughput or capillary-based screening for a bioactivity or biomolecule |
| 03/31/2005 | US20050069964 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC) |
| 03/31/2005 | US20050069942 Vaccine vector comprising isolated nucleic acid molecule which encodes sequence 2 linked to promoter |
| 03/31/2005 | US20050069878 Proteins associated with cell growth, differentiation, and death |
| 03/31/2005 | US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders. |
| 03/31/2005 | US20050069580 Compositions containing both sedative and non-sedative antihistamines and sleep aids |
| 03/31/2005 | US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies |
| 03/31/2005 | US20050069547 Binding protein; therapy for bone tumors |
| 03/31/2005 | US20050069276 Deuterated pyrazolopyrimidinones and drugs containing said compounds |
| 03/31/2005 | DE10340845A1 Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält A pharmaceutical combination preparation containing glycyrrhizic acid, zinc and a compound containing a thiol group or a metabolizable to this group |
| 03/31/2005 | CA2539590A1 Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases |
| 03/31/2005 | CA2539364A1 Carbohydrate composition and its use for the preparation of a medicament for treating or preventing pulmonary inflammation or acute respiration distress syndrome |
| 03/31/2005 | CA2539165A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | CA2539162A1 Cinnamoyl derivatives and use thereof |
| 03/31/2005 | CA2538960A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | CA2538760A1 Human .beta.-defensin secretion promoter |
| 03/31/2005 | CA2538366A1 Concurrent drugs |
| 03/30/2005 | EP1518855A1 Diaminopyrimidinecarboxa mide derivative |
| 03/30/2005 | EP1517989A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 03/30/2005 | EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases |
| 03/30/2005 | EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity |
| 03/30/2005 | EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors |
| 03/30/2005 | EP1517706A2 Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases |
| 03/30/2005 | EP1517673A1 Nasal composition comprising a mucopolysaccharide and propylene glycol |
| 03/30/2005 | EP1436007B1 Compounds for use as surfactants |
| 03/30/2005 | EP1407047A4 METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON GLUTATHIONE-S-TRANSFERASE Pi EXPRESSION |
| 03/30/2005 | EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders |
| 03/30/2005 | EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists |
| 03/30/2005 | EP1248597B1 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| 03/30/2005 | EP1194429B1 Potassium channel openers |
| 03/30/2005 | EP1183361B1 Gene therapy of pulmonary disease |
| 03/30/2005 | EP1105378B1 Quinazoline derivatives |
| 03/30/2005 | EP1091942B1 Potassium channel blocking agents |
| 03/30/2005 | EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors |
| 03/30/2005 | EP0980369B1 Sulfonamides for treatment of endothelin-mediated disorders |
| 03/30/2005 | CN1602425A Therapeutic and diagnostic uses of antibody specificity profiles |